THE Department of Health (DOH) on Monday said the recent spike in hand, foot, and mouth disease (HFMD) cases does not imply a dangerous outbreak but is a result of improved case reporting., This news data comes from:http://www.yamato-syokunin.com
“We cannot call this an outbreak,” said DOH Assistant Secretary Albert Domingo, explaining that 94 percent of the logged cases are still considered “suspect” and are not yet laboratory-confirmed.
Rise in HFMD cases due to better reporting, not outbreak
As of Aug. 9, the latest DOH data showed HFMD cases reaching 37,368 — over seven times higher than the 5,081 cases during the same period last year.
Despite the increase, Domingo emphasized that HFMD is not fatal and usually resolves within 7 to 10 days.
But DOH urged the public to remain cautious, especially during the wet season when transmission of the viral infection is more likely.
HFMD spreads through saliva, respiratory droplets, and contaminated surfaces.

Symptoms include fever, sore throat, rashes, and painful sores on the hands, feet, and inside the mouth.
In an earlier report, Health Secretary Ted Herbosa noted that the disease is highly contagious among children, because they spend more time indoors in the rainy season, making transmission easier.
While there is no specific cure, supportive treatment such as hydration, rest, and fever reducers can help patients recover faster.
- Israel ups pressure on Gaza City
- Meralco expects drop in power rates this month thanks to stronger peso
- DOE issues circular to consolidate electric vehicle recognition guidelines
- India warns Pakistan of more cross-border flooding due to heavy monsoon rains
- Putin ready to invade other countries, says Polish president
- Discayas to file raps vs protesters, will attend Senate hearing — lawyer
- 'God's Influencer' to become first millennial saint
- Isko files raps over demolition of sports complex
- DPWH fires Bulacan engineers, blacklists contractors over anomalous projects
- Woman accused of murdering her children faces New Zealand trial